ETF Holdings Breakdown of TRML

Stock NameTourmaline Bio Inc.
TickerTRML(USD) NASDAQ
TYPECommon Stock
CountryUSA

News associated with TRML

Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Target Price at $49.33
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last […] - 2025-05-08 05:04:55
Barclays PLC Acquires 26,733 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)
Barclays PLC grew its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 84.0% during the fourth quarter, Holdings Channel reports. The firm owned 58,566 shares of the company’s stock after purchasing an additional 26,733 shares during the period. Barclays PLC’s holdings in Tourmaline Bio were worth $1,187,000 as of its most […] - 2025-05-05 08:18:49
Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from Analysts at Chardan Capital
Stock analysts at Chardan Capital began coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a report issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 304.16% from the company’s current price. […] - 2025-04-25 07:24:47
Vanguard Group Inc. Acquires 43,652 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)
Vanguard Group Inc. boosted its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 4.1% in the 4th quarter, HoldingsChannel reports. The fund owned 1,106,125 shares of the company’s stock after buying an additional 43,652 shares during the quarter. Vanguard Group Inc.’s holdings in Tourmaline Bio were worth $22,432,000 at the end […] - 2025-04-16 07:28:51
Head to Head Survey: Tourmaline Bio (NASDAQ:TRML) vs. Vaxcyte (NASDAQ:PCVX)
Vaxcyte (NASDAQ:PCVX – Get Free Report) and Tourmaline Bio (NASDAQ:TRML – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Profitability This table compares Vaxcyte and Tourmaline Bio’s net […] - 2025-02-21 06:34:51

TRML institutional holdings

The following institutional investment holdings of TRML have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 12,682USD 199,615
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 12,682USD 199,615 2.2%
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 22,831USD 359,360
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 489USD 7,697
Total =48,684 USD 766,287
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.